Polaprezinc (Zinc L-carnosine) in Infants With Gastroesophageal Reflux
Key facts
- Who runs it
- University of Roma La Sapienza
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 1 Dec 2024
- Ended
- 1 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Zinc-L carnosine/Polaprezinc
- Thickened formula
- Record updated
- 5 May 2026
Who can take part
- Age
- 1 month to 12 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Patients with infant regurgitation accoding to Rome IV criteria
- Healthy infants aged 1-12 months
- I-GERQ-R score ≥ 16 at baseline
Who cannot take part
- Organic disease
- Past history of preterm birth or atopy
- Current or pregress use of pharmacological treatment for gastric acid suppression or current use of thickened formula
- Absence of informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants with GER.
Read full original descriptionShow less
Researchers will compare Zinc-L carnosine/Polaprezinc to a placebo (a look-alike substance that contains no drug) to see if Zinc-L carnosine/Polaprezinc works to treat infants with GER.
Participants will:
Take drug Zinc-L carnosine/Polaprezinc or a thickened formula every day for 8 weeks Visit the clinic once every 4 weeks for checkups and questionnaires
The 2 groups in the trial
- Zinc-L carnosine/PolaprezincTreatment being tested
This group will receive Zinc-L carnosine/Polaprezinc (Hepilor Liquido) 1 hour after meals: 2.5 ml twice a day in infants weighing \<5 kg or 5 ml twice a day in infants weighing \>5 kg.
- Thickened formulaExisting treatment, for comparison
Infants will receive thickened but not hydrolyzed formula
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Polaprezinc/Zinc L-carnosine (Hepilor) in Infants With Gastroesophageal Reflux
- Publications
- Zinc-L-Carnosine (Polaprezinc) in managing infant regurgitation: a two-center randomized controlled trial.Frontiers in pediatrics, 2026
- Record updated
- 5 May 2026